Exposure of YUMM cells to ultraviolet radiation (UVR) [21,22] or cisplatin [23] increases tumor mutation burden consequently improving tumor immune recognition, and such tumors are either rejected spontaneously [22], controlled with anti-CTLA4, continuous anti-PD1 administration [21], or combined (anti-CTLA4 plus anti-PD1) treatment [23]. Here, PDCD1 is linked to neoplasm.